PFWD Phase Forward (MM)

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate in two industry events this month: The 13th Annual DIA Workshop in Japan for Clinical Data Management (Booths 4 and 5) and VIB Pharma’s 11th Annual Clinical Trial Supply (Booth 3).

At DIA’s Workshop in Japan for Clinical Data Management, February 4-5 in Tokyo, three Phase Forward representatives will participate in key sessions including:

     

Who:

  Andy Brock, International Services Development Director, Phase Forward

What:

“New Approaches for CDM Infrastructure – Halfway up Mount Fuji: Japan Re-emerges as a Force in the Asia-Pacific Drug Development Market”

When:

Friday, February 5, 9:00-10:30 a.m. JST  

Who:

Aubrey Blazey, Architecture Consultant, Phase Forward

What:

“CDISC Reality: Simplifying Trial Data Extraction with CDISC ODM as a Web Service Interface”

When:

Friday, February 5, 11:00 a.m.-12:00 p.m. JST  

Who:

Ralph Johnson, Clinical Design Consultant, Phase Forward

What:

“CDISC Reality: Building an eCRF CDASH Library – A Case Study”

When:

Friday, February 5, 11:00 a.m.-12:00 p.m. JST

Later in the month at VIB Pharma’s 11th Annual Clinical Trial Supply, February 23-24 in London, Phase Forward will exhibit its Interactive Response Technology solution and lead the following session:

     

Who:

  Johan Verboven, Manager of IRT Project Management, Phase Forward

What:

“Cradle to Grave Tracking of Investigational Products – Pre-planning for Drug Reconciliation”

When:

Wednesday, February 24, 11:45 a.m.-12:15 p.m. GMT

Members of the media interested in speaking with Phase Forward should contact Maria Sumner at +44 1628 640743 or maria.sumner@phaseforward.com or Juli Greenwood at 781-672-3137 or jgreenwood@chenpr.com.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.